<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03255096</url>
  </required_header>
  <id_info>
    <org_study_id>NP39461</org_study_id>
    <secondary_id>2017-000357-39</secondary_id>
    <nct_id>NCT03255096</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)</brief_title>
  <official_title>Open-Label, Dose Escalation/Expansion Phase Ib Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability and clinical activity of
      RO6870810 in combination with venetoclax and when co-administered with rituximab in
      participants with relapse/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 28, 2017</start_date>
  <completion_date type="Anticipated">July 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 15, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Dose-Limiting Toxiciities (DLT)- Part 1</measure>
    <time_frame>Cycle (C) 1 (21 days)</time_frame>
    <description>DLT is defined as any of the toxicities- occurs within the first cycle for which the participant receives the full intended combination doses and number of administrations; is considered to be related to study treatment by the investigator; is not attributed to disease progression or another clearly identifiable cause.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Adverse Events (AEs) - Part 1</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Clinically Significant Changes in Vital Signs, Physical Examination, Clinical Laboratory Results and Electrocardiogram (ECG) Findings- Part 1</measure>
    <time_frame>Up to 36 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete Response (CR) Rate as Determined by Independent Radiological Central Review (ICR) Using Modified Lugano Response Criteria- Recommended Dose (RD) Expansion - Part 2</measure>
    <time_frame>Up to 36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events (AEs) - Part 2</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Clinically Significant Changes in Vital Signs, Physical Examination, Clinical Laboratory Results and Electrocardiogram (ECG) Findings- Part 2</measure>
    <time_frame>Up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Concentration (Cmax) of RO6870810 and its Potential Metabolites- Part 1 and Part 2</measure>
    <time_frame>Pre-dose Day 1,8,15; 0.25,0.5,1,2,4,6,8 hour (h) post-dose Day 1, 15; Day 2 C1; Pre-dose Day 1,8,15; 0.25h post-dose Day 1,8 C2; Pre-dose Day 1,15 C4; 0.25h post-dose Day 1 C4; Pre-dose, 0.25h post-dose Day 1 of subsequent even Cycles (Up to 36 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Serum Concentration (Cmin) of RO6870810 and its Potential Metabolites- Part 1 and Part 2</measure>
    <time_frame>Pre-dose Cycle 2 and all other subsequent even Cycles (Up to 36 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Maximum Concentration (tmax) of RO6870810 and its Potential Metabolites- Part 1 and Part 2</measure>
    <time_frame>Pre-dose Day 1,8,15; 0.25,0.5,1,2,4,6,8 hour (h) post-dose Day 1, 15; Day 2 C1; Pre-dose Day 1,8,15; 0.25h post-dose Day 1,8 C2; Pre-dose Day 1,15 C4; 0.25h post-dose Day 1 C4; Pre-dose, 0.25h post-dose Day 1 of subsequent even Cycles (Up to 36 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL) of RO6870810 and its Potential Metabolites- Part 1 and Part 2</measure>
    <time_frame>Pre-dose Day 1,8,15; 0.25,0.5,1,2,4,6,8 hour (h) post-dose Day 1, 15; Day 2 C1; Pre-dose Day 1,8,15; 0.25h post-dose Day 1,8 C2; Pre-dose Day 1,15 C4; 0.25h post-dose Day 1 C4; Pre-dose, 0.25h post-dose Day 1 of subsequent even Cycles (Up to 36 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution (Vd) of RO6870810 and its Potential Metabolites- Part 1 and Part 2</measure>
    <time_frame>Pre-dose Day 1,8,15; 0.25,0.5,1,2,4,6,8 hour (h) post-dose Day 1, 15; Day 2 C1; Pre-dose Day 1,8,15; 0.25h post-dose Day 1,8 C2; Pre-dose Day 1,15 C4; 0.25h post-dose Day 1 C4; Pre-dose, 0.25h post-dose Day 1 of subsequent even Cycles (Up to 36 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) of RO6870810 and its Potential Metabolites- Part 1 and Part 2</measure>
    <time_frame>Pre-dose Day 1,8,15; 0.25,0.5,1,2,4,6,8 hour (h) post-dose Day 1, 15; Day 2 C1; Pre-dose Day 1,8,15; 0.25h post-dose Day 1,8 C2; Pre-dose Day 1,15 C4; 0.25h post-dose Day 1 C4; Pre-dose, 0.25h post-dose Day 1 of subsequent even Cycles (Up to 36 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response (CR) Rate as Determined by the Investigator Based on the Modified Lugano Response Criteria- Part 1 and Part 2</measure>
    <time_frame>Up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response (CR) Rate, as Determined by the ICR and by the Investigator on the Basis of CT Scans Alone- Part 1 and Part 2</measure>
    <time_frame>Up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate, as Determined by the ICR and by the Investigator on the Basis of Modified Lugano Response Criteria- Part 1 and Part 2</measure>
    <time_frame>Up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate, as Determined by the ICR and by the Investigator on the Basis of CT Scans Alone- Part 1 and Part 2</measure>
    <time_frame>Up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)- Part 1 and Part 2</measure>
    <time_frame>Up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)- Part 1 and Part 2</measure>
    <time_frame>Up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-Free Survival (EFS)- Part 1 and Part 2</measure>
    <time_frame>Up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-Free Survival (DFS)- Part 1 and Part 2</measure>
    <time_frame>Up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)- Part 1 and Part 2</measure>
    <time_frame>Up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-Life (t1/2) of RO6870810 and its Potential Metabolites- Part 1 and Part 2</measure>
    <time_frame>Pre-dose Day 1,8,15; 0.25,0.5,1,2,4,6,8 hour (h) post-dose Day 1, 15; Day 2 C1; Pre-dose Day 1,8,15; 0.25h post-dose Day 1,8 C2; Pre-dose Day 1,15 C4; 0.25h post-dose Day 1 C4; Pre-dose, 0.25h post-dose Day 1 of subsequent even Cycles (Up to 36 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Ant-Drug Antibodies (ADA) Against Rituximab - Part 1 and Part 2</measure>
    <time_frame>Pre-dose, End of Infusion Day 1 Cycle 1; Pre-dose Day 1 Cycle 2, 3, 4 , 6 and all other even Cycles (Up to 36 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">94</enrollment>
  <condition>Diffuse Large B-cell Lymphoma (DLBCL)</condition>
  <arm_group>
    <arm_group_label>Dose Escalation Phase (Part 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive either RO6870810 and venetoclax or RO6870810 and venetoclax along with rituximab until disease progression, unacceptable toxicities or withdrawal from treatment for other reasons, or death.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Phase (Part 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive RO6870810 and venetoclax along with rituximab (or RO6870810 and venetoclax, if the combination of the 3 drugs is not tolerable) at a recommended dose established in dose escalation phase until disease progression, unacceptable toxicities or withdrawal from treatment for other reasons, or death.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO6870810</intervention_name>
    <description>RO6870810 subcutaneously (SC) at dose of 0.30, 0.45, or 0.65 milligram per kilogram (mg/kg) on Days 1-14 of 21-day cycles.</description>
    <arm_group_label>Dose Escalation Phase (Part 1)</arm_group_label>
    <arm_group_label>Expansion Phase (Part 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>Venetoclax tablets orally at dose of 400 mg once daily (QD) continuously for 21 days.</description>
    <arm_group_label>Dose Escalation Phase (Part 1)</arm_group_label>
    <arm_group_label>Expansion Phase (Part 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Rituximab intravenously (IV) at dose of 375 mg/m^2 weekly during the first 21-day cycle (C1) and on day 1 of each cycle thereafter.</description>
    <arm_group_label>Dose Escalation Phase (Part 1)</arm_group_label>
    <arm_group_label>Expansion Phase (Part 2)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2.

          2. Life expectancy &gt;3 months as per investigator's assessment.

          3. Participantts with diffuse large B-cell lymphoma (DLBCL) relapsed or refractory to ≥ 1
             course of chemotherapy including an anti-CD20 monoclonal antibody, and not eligible
             for autologous stem cell transplantation (ASCT) (including due to chemorefractory
             disease). Participants with transformed FL are eligible, provided DLBCL histology is
             biopsy-confirmed prior to study entry and a treatment regimen as described above has
             been administered. The Sponsor retains the option to limit the number of participants
             enrolled with transformed FL.

          4. Acceptable liver function, as specified below:

               -  Total bilirubin ≤ 2 times upper limit of normal (ULN). (Participants with known
                  Gilbert's disease who has serum bilirubin ≤ 3 × ULN may be enrolled).

               -  Aspartate transaminase (AST; SGOT), alanine transaminase (ALT; SGPT) ≤ 2.5 × ULN,
                  (or ≤ 5 × ULN if tumor involvement (liver) is present).

               -  Gamma-glutamyl transferase (GGT) alkaline phosphatase ≤ 2.5 × ULN.

          5. Acceptable renal function, as specified below::

             • Creatinine clearance (CrCl) calculated by Cockroft-Gault formula of ≥ 60 mL/min.

          6. Acceptable hematologic status (growth factors cannot be used within the previous 7
             days), as specified below:

               -  Absolute neutrophil count (ANC) ≥ 1000 cells/μL

               -  Hemoglobin ≥ 9 g/dL

               -  Platelet count ≥ 75,000 (platelets/μL)

          7. Serum calcium (corrected for albumin) level at or below the ULN (treatment of
             hypercalcemia is allowed and participant may enroll if hypercalcemia returns to normal
             with standard treatment).

          8. Acceptable coagulation status, as specified below:

               -  Prothrombin time (PT)/partial thromboplastin time (PTT) ≤ 1.2 × ULN (unless
                  receiving anticoagulation therapy, if receiving anticoagulation therapy,
                  eligibility will be based upon international normalized ratio [INR]).

               -  INR ≤ 1.6 (unless receiving anticoagulation therapy).

               -  If receiving warfarin: INR ≤ 3.0 and no active bleeding (i.e., no bleeding within
                  14 days prior to first dose of study therapy).

          9. Acceptable method of contraception

        Exclusion Criteria

          1. Current central nervous system (CNS) lymphoma or leptomeningeal infiltration.

          2. New York Heart Association (NYHA) Class III or IV cardiac disease, myocardial
             infarction, within the past 6 months, unstable arrhythmia, or known pericardial
             disease.

          3. Fredericia-corrected QT interval (QTcF) &gt;470 msec (female) or &gt;450 msec (male), or
             history of congenital long QT syndrome.

          4. Any electrocardiogram (ECG) abnormality, which in the opinion of the Investigator
             would preclude safe participation in the study.

          5. Active, uncontrolled bacterial, viral, or fungal infections, within 7 days of study
             entry requiring systemic therapy.

          6. Known clinically important respiratory impairment

          7. Grade ≥ 3 sensory or motor neuropathy.

          8. Any Grade &gt;1 (according to the NCI CTCAE 4.03) adverse reaction unresolved from
             previous treatments and not readily managed and controlled with supportive care.

          9. Serious non-malignant disease that could compromise protocol objectives in the opinion
             of the Investigator and/or the Sponsor.

         10. History of progressive multifocal leukoencephalopathy (PML).

         11. History of other malignancy within 2 years prior to screening, except for ductal
             carcinoma in situ not requiring chemotherapy, appropriately treated carcinoma in situ
             of the cervix, non-melanoma skin carcinoma, low-grade, localized prostate cancer
             (Gleason score ≤ 7) not requiring treatment or appropriately treated Stage I uterine
             cancer.

         12. Completion of ASCT within 100 days prior to Day 1 of Cycle1.

         13. Prior standard or investigational anti-cancer therapy, as specified below:

               -  Radio-immunoconjugate within 12 weeks prior to Day 1 of Cycle 1.

               -  Monoclonal antibody or antibody-drug conjugate (ADC) therapy within 3 weeks prior
                  to Day 1 of Cycle 1.

               -  Radiotherapy, chemotherapy, or targeted small-molecule therapy within 2 weeks
                  prior to Day 1 of Cycle 1.

         14. History of major solid organ transplant (i.e., heart, lungs, liver and kidney).

         15. History of an allogeneic bone marrow transplant.

         16. Major surgical procedure within 28 days prior to Day 1 of Cycle 1.

         17. Treatment with systemic corticosteroids ≥ 20 mg/day prednisone or equivalent, for
             non-lymphoma treatment reasons. For lower acceptable doses, documentation of a stable
             dose for at least 4 weeks prior to Day 1 of Cycle 1 is required.

         18. Treatment with strong to moderate CYP3A inhibitors or moderate CYP3A inducers within 7
             days prior to the first dose of study treatment.

         19. Treatment with strong CYP3A inducers within 14 days prior to the first dose of study
             treatment of RO6870810/venetoclax.

         20. Consumption of grapefruits, grapefruit products, Seville oranges (including marmalade
             that contains Seville oranges), or star fruit within 3 days prior to the first dose of
             venetoclax.

         21. Participants who are currently receiving any other investigational agent or have
             received an investigational agent within 30 days or 5 half-lives prior to study entry,
             whichever is longer.

         22. Prior treatment with small molecule bromodomain and extra terminal (BET) family
             inhibitor.

         23. Known to be human immunodeficiency virus (HIV) positive.

         24. Presence of positive test results for hepatitis B surface antigen (HBsAg) or hepatitis
             C antibodies (HcAb) (for participants receiving regimen including rituximab)

         25. Pregnant or breastfeeding female.

         26. Significant allergy to a biological pharmaceutical therapy that, in the opinion of the
             Investigator, poses an increased risk to the participant.

         27. Uncontrolled cancer pain. Participants requiring pain medication must be on a stable
             regimen at study entry. Symptomatic lesions amenable to palliative radiotherapy should
             be treated prior to enrollment.

         28. History of severe allergic or anaphylactic reaction to humanized or murine monoclonal
             antibodies (for participants receiving regimen including rituximab).

         29. Known sensitivity or allergy to murine products or any component of RO6870810,
             venetoclax, or rituximab.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Chair</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: NP39461 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>+1 888-662-6728</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305-5820</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Inst. ; Dept. of Medical Oncology</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center; Center for Lymphoid Malignancies</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Institute - Blythe</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center Department of Lymphoma &amp; Myeloma</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre-East Melbourne</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Righospitalet, Haematologisk Klinik</name>
      <address>
        <city>Kobenhavn</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau; Servicio de Hematologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Duran i Reynals; Servicio de Hematologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>START Madrid-FJD, Hospital Fundacion Jimenez Diaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Denmark</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 31, 2017</study_first_submitted>
  <study_first_submitted_qc>August 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2017</study_first_posted>
  <last_update_submitted>April 24, 2018</last_update_submitted>
  <last_update_submitted_qc>April 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venetoclax</mesh_term>
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

